OncoMatch/Clinical Trials/NCT05607095
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Is NCT05607095 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Lifileucel (LN-144/LN-145) for uveal melanoma.
Treatment: Lifileucel (LN-144/LN-145) — This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage IV
metastatic Uveal Melanoma; unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
refractory to at least 1 prior line of systemic therapy
Cannot have received: organ allograft or prior cell transfer therapy that included a non-myeloablative or myeloablative chemotherapy regimen
Patients who have received an organ allograft or prior cell transfer therapy that included a non-myeloablative or myeloablative chemotherapy regimen.
Lab requirements
Blood counts
ANC ≥ 1000/mm3; Hemoglobin ≥ 9.0 g/dL; Platelet ≥ 100,000/mm3; transfusions or growth factors not allowed 28 days prior to signing ICF and through Screening
Kidney function
Estimated creatinine clearance (eCrCl) ≥ 40 mL/min using Cockcroft-Gault formula
Liver function
ALT and AST ≤ 3 × ULN; patients with liver metastasis ≤ 5 × ULN; total bilirubin ≤ 2 mg/dL (≤ 3 mg/dL for Gilbert's syndrome)
Cardiac function
LVEF ≥ 45%; NYHA functional classification ≤ Class 1; patients ≥ 60 years with cardiac history require stress test; irreversible wall movement abnormalities excluded
Patients must have the following hematologic parameters: ANC ≥ 1000/mm3, Hemoglobin ≥ 9.0 g/dL, Platelet ≥ 100,000/mm3. Patients must have adequate organ function: ALT and AST ≤ 3 × ULN; patients with liver metastasis ≤ 5 × ULN; eCrCl ≥ 40 mL/min; total bilirubin ≤ 2 mg/dL (≤ 3 mg/dL for Gilbert's syndrome). LVEF <45% or NYHA > Class 1 excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Westchester · Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify